

Investigation of Wound Healing and Anticancer Properties of *in vitro* Grown Sesame Plant Extract in L929, A549, and MCF-7 Cell Lines and Transcriptomic Analyses of *Cas3*, *Cas9*, and BCL-XL Genes in the Sesame Extract Treated Cells

Sevil Yeniocak , Selin Galatalı , İrem Demir , Aysel Uğur , [Nurdan Sarac](#)^{*} , [Ergun Kaya](#)^{*}

Posted Date: 27 June 2023

doi: 10.20944/preprints202306.1866.v1

Keywords: Sesamum orientale L. cv. "Gökova"; L929 fibroblast cells; A549 lung epithelial cells; MCF-7 breast epithelial cells; Cisplatin; BCL-XL gene; Cas3 and Cas9 genes



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Investigation of Wound Healing and Anticancer Properties of *In Vitro* Grown Sesame Plant Extract in L929, A549, and MCF-7 Cell Lines and Transcriptomic Analyses of *Cas3*, *Cas9*, and *BCL-XL* Genes in the Sesame Extract Treated Cells

Sevil Yeniocak ¹, Selin Galatalı ¹, İrem Demir ², Aysel Uğur ³, Nurdan Saraç ^{2,*} and Ergun Kaya ^{1,*}

¹ Muğla Sıtkı Koçman University, Faculty of Science, Molecular Biology and Genetics Department, Kotekli, 48000, Muğla, Turkey; sevelyeniocak@outlook.com (S.Y.); selingalatali@mu.edu.tr (S.G.)

² Muğla Sıtkı Koçman University, Faculty of Science, Biology Department, Kotekli, 48000, Muğla, Turkey, iremdemir@posta.mu.edu.tr

³ Gazi University, Faculty of Dentistry, Department of Basic Sciences, 06560, Teknikokullar, Yenimahalle, Ankara, Turkey; ayselugur@gazi.edu.tr

* Correspondence: nsarac@mu.edu.tr (N.S.); ergunkaya@mu.edu.tr (E.K.); Tel.: +90-(544)-202-41-64 (N.S.); +90-(539)-626-66-04 (E.K.)

Abstract: In addition to its use as a food additive, sesame is also very popular in conventional drugs because of its antifungal, anticancer, analgesic, antioxidant, and antiproliferative, vitamin B and E supplier, serum cholesterol and blood pressure-lowering, wound healing potential. In this study, the cytotoxicity, wound healing, and anticancer (antiproliferation) properties of the extract obtained from *in vitro* cultures of *Sesamum orientale* L. cv. "Gökova" were investigated using in L929 fibroblast, MCF-7 breast, and A549 lung epithelial cell lines. In our study, the cisplatin was also used as a control group to compare the anticancer efficacy of our plant extract. The IC₅₀ values obtained from cell treatments were 922.73 µg.ml⁻¹ (plant extract) and 33.09 µg.ml⁻¹ (cisplatin) for A549 µg.ml⁻¹, 1837.07 µg.ml⁻¹ (plant extract) and 19.27 µg.ml⁻¹ (cisplatin) for MCF-7, and 154.70 µg.ml⁻¹ (plant extract) for L929, respectively. The subcytotoxic doses of the treated plant extract provided the healing of artificially created wounds on L929 fibroblast cell cultures within 48 hours. For the evaluation of the anticancer activity, it was also determined that transcriptomic analyzes of *BCL-XL* gene, which is negatively correlated with apoptotic pathway, and *Cas3* and *Cas9* genes, which are positively correlated with apoptotic pathway, showed a statistically significant increase in A549 and MCF-7 cell lines treated with plant extract or cisplatin. In the light of the results obtained from the present study, it was seen that sesame plant extract may have wound healing potential at decreasing doses and anticancer activity potential at increasing doses. The present study can be a useful resource for the development of a drug with wound healing and/or antiproliferative potential, with applications to be made in different cell lines in the future.

Keywords: *Sesamum orientale* L. cv. "Gökova"; L929 fibroblast cells; A549 lung epithelial cells; MCF-7 breast epithelial cells; cisplatin; *BCL-XL* gene; *Cas3* and *Cas9* genes

1. Introduction

There are about 40 different species of sesame plant belonging to the Pedaliaceae family and the *Sesamum* genus. Sesame, which has been cultivated since ancient times, has many wild and cultivated varieties [1]. In addition to its use as a food additive, it is also widely used in traditional medicine due to its properties of demulcent, mildly laxative, emollient [2], antifungal [3], antioxidant [4], analgesic [5], anticancer and antiproliferative [6], vitamin B and E supplier [7], serum cholesterol (lipid) and blood pressure-lowering potential [8,9].

Many studies on biochemical and biological activities have been carried out on the seed and oil of the sesame plant [7,10–12]. It is a very valuable agricultural crop, especially in its seeds with high amino acid content, thanks to its protein content of up to 28% and oil content of up to 55% [13]. It has

also been proven by studies that this seed oil contains saturated fatty acids (14%), monounsaturated fatty acids (39%) and, polyunsaturated fatty acids (46%) [1]. The most important bioactive components of sesame are sesamin, which protects the liver from oxidative destruction, and sesamol, which is a kind of insecticide. These two components are the major lignans of sesame seed oil [14]. Sesamin is also a noncompetitive inhibitor, which plays an important role on its anti-inflammatory effect [15]. In addition to these two basic components, sesame contains two more components as sesamol and tocopherol [16].

Although the use of other vertebrates, including humans, in many scientific studies in the field of health brings convenience, as in every study, it also brings ethical problems. The most effective solution for the ethical problems that may occur was the use of *in vitro* cell culture method [17,18]. Cell culture is the method of providing human body conditions to the cells under the appropriate temperature, humidity and carbon dioxide environment in a medium containing various cell types isolated from plants or mammals, and nutrients such as amino acids, vitamins, inorganic salts, serum and glucose. By imitating human body conditions, cells are allowed to reproduce in an artificial environment, and it helps to lay the foundations of many studies, from researching metabolomics, transcriptomics, proteomics and other cellular processes at the level of basic sciences to drug development and understanding drug action pathways, and gene therapy principles through cell culture studies [19,20].

L929 fibroblast cell cultures originating from the mouse C3H/An connective tissue have been used in studies such as investigation of the *in vitro* oligo-hydroxyalkanoates effect on the growing, the anti-inflammatory and antioxidant properties of the chondroitin sulfate, the cytochemical properties of the fibroblast-preadipocyte relationships, and the acute activation of glucose uptake, in addition to virus studies. The cells contained in this culture are also HPRT+ and APRT+ [21–24]. A549 lung epithelial cell cultures, which have the ability to synthesize lecithin by using the cytidine diphosphocholine pathway, have been used in studies such as inhibition of cancer cells, antiproliferation and identification of its mechanisms, and investigation of the effects of insulin and insulin-like growth factor on apoptosis and cell proliferation [25,26]. MCF-7 breast epithelial cell cultures, which are capable of expressing the WNT7B oncogene, have been used in studies on the inhibition of telomerase activity and the effect of estrogen in the apoptotic pathway, as well as in studies on inhibition and antiproliferation of cell division and understanding these mechanisms [27–29]. Although cisplatin is used alone, it is mostly used in combination with other cytostatic drugs. Cisplatin destroys cells that can cause certain types of cancer such as testicular tumors, ovarian tumors, lung tumors, etc. It can be used as a control group in cell culture studies to determine the effectiveness of antiproliferation [30–33].

By examining the gene expressions in tissues and/or cells at the level of mRNA in terms of form and quantity, transcriptomic analyzes provide great contributions to the understanding of the importance of these genes for the organism, as well as learning the functions of genes [34,35]. In these analyzes, on the other hand, is the simultaneous study of mRNA transcripts generated by transcription from the cell genome. It aims to measure the expression level of a selected subset or all of the genes, based on the amount of RNA present in a sample [36,37]. With these analyzes, it is possible to identify genes related to disease and physiological processes, to reveal the structural-functional interactions between genes, to reveal the roles of genes in development, to reveal their expression profiles, and to compare different organisms on the genetic basis [38,39].

In this context, the current work purposed to investigate the wound healing and antiproliferative properties of the plant extract of *in vitro* grown *S. orientale* L. cv. "Gökova" using L929 fibroblast, MCF-7 breast and, A549 lung epithelial cell lines. Another aim of the study, in MCF-7 and A549 cell lines treated with the plant extract or cisplatin, was to examine at the transcriptional level of CRISPR-associated system 3 (CAS3) endonuclease [40], CRISPR-associated system 9 (CAS9) endonuclease [41], and B-cell lymphoma XL (anti-apoptotic, BCL-XL) [42] genes expressions, which we think are effective in metabolic processes such as cell growth and division, control of apoptotic pathways and cellular cycle. This study is derived from a part of PhD student Sevil Yeniocak's doctoral thesis.

2. Results

2.1. Wound healing properties of sesame plant extract

In order to determine the subcytotoxic doses of the applied plant extract in wound healing trials, we primarily determined the cytotoxicity of the extract. The cytotoxic effects of *in vitro* grown *S. orientale* L. cv. “Gökova” plant extract were performed by MTT assay using L929 fibroblast cell line. According to the MTT test result, the IC₅₀ value of the plant extract was calculated as 154,70±7,16 µg.ml⁻¹ (Figure 1).




Figure 1. The effect of the *in vitro* grown *S. orientale* L. cv. “Gökova” plant extract applied at doses below the IC₅₀ value on the viability of L929 fibroblast cells.

The wound healing activity of the plant extract applied at subcytotoxic doses of IC₅₀ was determined by *in vitro* scratch test performed by incubation of the plant extract for 24-48 hours periods on L929 fibroblast cells. According to the results of the *in vitro* scratch test, it had a positive effect on the healing of the wounds formed on L929 fibroblast cell cultures, after 48 hours in decreasing subdoses of the plant extracts. In plant extract applications at reduced subdoses of IC₅₀, wound healing was quite evident at 48 hours after 25 µg.ml⁻¹ plant extract treatments (Figure 2).




Figure 2. Treatment of the *in vitro* grown *S. orientale* L. cv. "Gökova" plant extract wound healing properties. Snapshots were taken immediately after introducing the artificial wound 0 h, 24 h and 48 h after the extract concentration treated were 0 (control), 25, 50, 100, and 150 $\mu\text{g.ml}^{-1}$.

2.2. Anticancer properties of sesame plant extract

In the A549 lung epithelium cell line treated with the different concentration of the *in vitro* grown *S. orientale* L. cv. "Gökova" plant extract, the cell viability inhibition percentage was variable, manifesting a concentration related effect. While at the highest concentration of the treated extract (4000 $\mu\text{g.ml}^{-1}$), the inhibition was $73.25 \pm 5.03 \%$, at the lowest concentration of the treated extract (125 $\mu\text{g.ml}^{-1}$), it was $24.41 \pm 1.99 \%$ (Figure 3).

Additionally, in the MCF-7 mammary epithelium cell line treated with the different concentration of the plant extract, the percentage of cell viability inhibition was $16.01 \pm 9.23 \%$ at 125 $\mu\text{g.ml}^{-1}$, and $66.14 \pm 5.95 \%$ at 4000 $\mu\text{g.ml}^{-1}$ (Figure 3).

When the plant extract effect on both cell lines was compared in the treatment of similar concentrations, it was observed that the extract caused a significant inhibition on the A549 cell line at all treatment doses (especially at 1000 $\mu\text{g.ml}^{-1}$ concentration) (Figure 3).

In order to compare the significance of the antiproliferative activity of the plant extract treatment, cisplatin was treated at concentrations of 3.1 $\mu\text{g.ml}^{-1}$ to 100 $\mu\text{g.ml}^{-1}$ in both cell lines as control group. In the A549 lung epithelium cell line treated with the different concentration of cisplatin, the percentage of cell viability inhibition was ranged from $0.0 \pm 1.7 \%$ (3.1 $\mu\text{g.ml}^{-1}$) to $84.96 \pm 0.81 \%$ (100 $\mu\text{g.ml}^{-1}$), $\text{IC}_{50} = 43 \pm 2.15$. Furthermore, in the MCF-7 mammary epithelium cell line treated with the different concentration of cisplatin, the percentage of cell viability inhibition was ranged from $28.33 \pm 3.49 \%$ (3.1 $\mu\text{g.ml}^{-1}$) to $64.89 \pm 1.46 \%$ (100 $\mu\text{g.ml}^{-1}$), $\text{IC}_{50} = 12.5 \pm 1.79$ (Figure 4).




Figure 3. Dose–response graph of the *in vitro* grown *S. orientale* L. cv. “Gökova” plant extract for viability inhibition of MCF-7 and A549 cell lines.





Figure 4. Dose–response graph of cisplatin for viability inhibition of MCF-7 and A549 cell lines.

2.3. Transcriptomic analyzes in treated cell lines

Graphs were created by calculating the mean of the Ct values (with standard errors and standard deviations) obtained after Real-Time PCR carried out to specified the expression levels of *BCL-XL*, *Cas3* and *Cas9* genes at the mRNA level in A549 and MCF-7 cell lines.


When the data for the A549 cell line were examined, an increase was monitored in the mRNA expression level of the *BCL-XL* gene, which is negatively correlated with the apoptotic pathway, in the extract and cisplatin groups, respectively, compared to the control group, whereas this rise was not statistically remarkable. A statistically remarkable enhancement was observed in the mRNA expression levels of *Cas3* and *Cas9* genes, which are positively correlated with the apoptotic pathway, in the extract and cisplatin applied groups compared to the control group (Figure 5).



*, $p \leq 0,05$; **, $p \leq 0,01$; ***, $p \leq 0,001$.

Figure 5. Relative mRNA expression plot of *BCL-XL*, *Cas3* and *Cas9* genes in A549 cell line (Control: No substance application; Extract: treated with $922.73 \mu\text{g.ml}^{-1}$ *S. orientale* plant extract for 6 hours; Cisplatin: Anti-cancer treated with chemotherapeutic drug at a concentration of $33 \mu\text{g.ml}^{-1}$ for 6 hours).

When the data for the MCF-7 cell line were analyzed, the *BCL-XL* gene, whose mRNA expression level was suppressed in the apoptotic pathway, did not show a significant change in the cell lines treated with extract when compared to the control group. However, it showed a statistically considerable decrease in the cisplatin applied group. A significant increase was detected in the extract and cisplatin applied groups compared to the control group in *Cas3* and *Cas9* genes, whose mRNA expression level was induced in the apoptotic pathway. The fact that the treatment of breast cancer cells (MCF-7) with $922.73 \mu\text{g.ml}^{-1}$ *S. orientale* plant extract for 6 hours induced the expression of *Cas9* gene more than cisplatin treatment, which is used as an anti-cancer drug and causes serious side effects, is a very remarkable result in this study (Figure 6).



*, $p \leq 0,05$; **, $p \leq 0,01$; ***, $p \leq 0,001$.

Figure 6. Relative mRNA expression plot of *BCL-XL*, *Cas3* and *Cas9* genes in MCF-7 cell line (Control: No substance applied; Extract: $1837.07 \mu\text{g.ml}^{-1}$ *S. orientale* plant extract treated for 6 hours; Cisplatin: Anti - treated with a cancerous chemotherapeutic drug at a concentration of $42.38 \mu\text{g.ml}^{-1}$ for 6 hours).

3. Discussion

3.1. The plant extract in decreasing subcytotoxic doses is effective on wound healing

Almost all medicinal plants have always played important role as pharmacologically for every country in the world. These plants are influenced to cure different illnesses and deactivate possible epidemics, to add flavor to meals and to conserve foods [43,44]. These plants are considered valuable sources of conventional drugs and the most synthetic drugs are produced from them. Bioactive components produced by these plants are largely responsible for the different metabolic pathways of plant species used throughout the world [45,46].

studying the influences of medicinal plant species on health is important for the invention or creation of novel drugs. In this context, in the current study, the wound healing and anticancer properties of sesame plant, whose seeds and oil are an important plant in traditional medicine, were investigated. The subcytotoxic doses (IC_{50} , $154,70 \pm 7,16 \mu\text{g.ml}^{-1}$) of the treated *in vitro* grown *S. orientale* L. cv. "Gökova" plant extract provided the healing of artificially created wounds on L929 fibroblast cell cultures within 48 hours (Figure 2). Wound is defined as the deterioration of the anatomical and functional integrity of healthy tissues [47]. Wound healing is the systematic, biochemical and cellular cases induced by trauma, resulting in the production of new tissue. The main principle of wound healing is to decrease the damage of tissues, to ensure sufficient tissue oxygenation and perfusion, as well as appropriate nutrition and moistening of the tissue [48,49]. In 2019 Bolla *et al.* investigated the wound healing characteristics of the methanolic extract of *Aristolochia saccate* on L929 cell line. In this study, they determined 93.52% wound closure 48 hours after the plant extract treatment [50]. In the same year, Alsawalha *et al.* used the L929 fibroblast cell line to study the wound healing potential of *Dioscorea villosa* extract. In this study, they found that $125 \mu\text{g.ml}^{-1}$ of plant extract induced 88.58% cell migration in L929 fibroblast cell [51]. Similarly, in 2022, Danna *et al.* used the L929 fibroblast cell line

to determine the wound healing potential of *Peucedanum ostruthium* leaf and rhizome extracts. In this study, L929 fibroblast cells represented parallel wound closure stimulation with both extracts (IC₅₀, 801 for leaf extract; IC₅₀, 385 for rhizome extract) [52]. As in our study, these studies in the literature have shown that these plants used in traditional medicine may have wound healing potential and these results also support our study.

3.2. The plant extract in increasing doses is effective on antiproliferation

Although there are many synthetic drugs designed from raw materials obtained from plant extracts, the diversity of diseases that people are exposed to and the different responses of people to diseases increase the importance of drug studies. It is estimated that acceptable therapy is available for only one-third of known human diseases. For this reason, it is important for future studies to reveal the biological characteristics of species of medical importance [53,54]. The use of herbal products in cancer treatment can prevent health problems that may occur relatively. Therefore, studies on the chemical components of various plant sources used as anticancer agents have increased in recent years [55]. For example, curcumin from soybeans, polyphenols from green tea, resveratrol from grapes, lycopene from tomatoes, and crocetin from saffron are compounds that are effective in cancer treatment [56–58].

In the current study, the anticancer properties of *in vitro* grown *S. orientale* L. cv. “Gökova” plant extract were also investigated using MCF-7 mammary epithelium and A549 lung epithelium cell lines. The antiproliferative effect of the extract was also increased with increasing doses for both lines. In the MCF-7 cell line, cell division inhibition was determined as ~66.14% for the highest dose of plant extract applied. In 2020, Nivethitha *et al.* investigated the anticancer properties of *S. indicum* plant extract in MCF-7 cell line, similar to our study. In the study, they found that the anticancer activity of the plant extract (IC₅₀, 148.76 µg.ml⁻¹) was quite good [59]. Siao *et al.* investigated the anti-proliferation properties and action mechanism of *S. indicum* seeds, in a study they conducted in 2015 and they used MCF-7 cell lines as in our work. Their results showed that the cell viability inhibition the dose-dependently (10 and 50 µM sesamin decreased the cell viability by 18 and 30% respectively) increased [60]. All these studies and the results obtained from some other studies in the literature are in line with the results obtained from our study [61,62].

On the other hand, in the A549 lung epithelium cell line, cell division inhibition percentage was determined as ~73.25% for the highest dose of plant extract applied. In a 2017 study by Watanabe *et al.*, it was proven that sesamol indicated anticancer properties against A549 cell lines at 50 µM concentration and 6 hours of treatment. The study showed that this effect of sesamin makes it a potential anticancer agent because lignan has the ability to prevent DNA damage. It has also been reported that sesamin's ability to decrease COX-2 gene expression in the A549 cell line inactivates the inflammatory response that reduces restenosis due to inhibition of the PI3K-Akt pathway [63,64]. All these results are also in matching with the results obtained in our work.

3.3. CRISPR-associated system 9 and 3 positively correlated with apoptotic pathway

The development and cell differentiation is a biological process regulated and controlled by genes. When this regulation is disrupted as a result of genetic change, the end point is the emergence of malignant appearance. For this reason, it may be useful to look at gene expression levels that are thought to be effective in metabolic processes in order to understand cancer and the mechanisms that cause cancer [40,41,65]. In this context, in our study, the expressions of CRISPR-associated system 3 (CAS3) endonuclease, CRISPR-associated system 9 (CAS9) endonuclease, and B-cell lymphoma XL (BCL-XL, anti-apoptotic) genes, which are responsible for the apoptotic pathway, were investigated before and after *in vitro* grown *S. orientale* L. cv. “Gökova” plant extract treatment in MCF-7 breast cancer and A549 lung epithelium cell lines.

Han *et al.* in 1999, investigated the antiproliferative properties of curcumin in BKS-2 immature B lymphoma cell line. They found that the curcumin decreased the BCL-XL expression as well as the tumor suppressor gene p53 in B cells [66]. In addition to inhibiting apoptosis, BCL-XL has also been reported to be a key regulator of tumor progression, cell migration and other important cellular

functions [67]. In the current study, the anti-apoptotic *BCL-XL* expression is suppressed when the cell receives apoptosis signal. Therefore, the expression level is expected to decrease in the extract and cisplatin administered groups compared to the control group [68]. According to the results obtained, it is thought that the *BCL-XL* gene, whose expression was not suppressed after the extract and cisplatin application, is not related to the apoptotic pathway in A549 cancer cells. The expected effect was observed in MCF-7 cells treated with cisplatin. There was no significant effect of “Gökova” sesame plant extract on the *BCL-XL* gene.

In our study, it was also determined that the *Cas3* and *Cas9* expression levels, which are known to be positively correlated with the apoptotic pathway, were significantly increased in the extract and cisplatin applied groups compared to the control group. This showed that both cisplatin and plant extract could be associated with cell death by suppressing A549 lung epithelium cell proliferation and inducing apoptosis. It can be said by looking at *Cas3* mRNA expression levels that cisplatin used in chemotherapy promotes lung cancer cells to apoptosis at a higher rate compared to the study material, “Gökova” sesame plant extract. However, the high toxic effect of cisplatin [69] is known through studies, and the serious side effects caused by this situation show that the extract obtained from “Gökova” sesame plant extract can be used instead of cisplatin. When *Cas9* mRNA expression levels on MCF-7 cells were examined, it was observed that the plant extract induced apoptosis more than cisplatin. This shows that “Gökova” sesame plant extract can also be preferred instead of cisplatin, which is already known to have high toxic properties. A study by Özkan *et al.* in 2021 confirmed that small extracellular vesicles of *Allium sativum* induce caspase-mediated apoptosis and inhibit the proliferation of cancer cells. In this work, the A549 cell line was used and a significant increase in some proapoptotic genes for cancer cells was also noted in parallel with *Cas3* gene expression levels. After the extract application, *Cas9* gene expression increased 2.5 times [70]. These results are also in agreement with the results obtained from the present work.

4. Materials and Methods

4.1. Plant Material and In vitro Culture establishment

The *S. orientale* cv. “Gökova” seeds grown in the collection gardens (Figure 7A, B) were derived from Muğla Metropolitan Municipality, Agricultural Services Unit, Local Seed Bank (the cooperation protocol no: 10452259-030.02-1240). For *in vitro* culture initiation, surface sterilization of seeds was used by modifying the methods previously developed by Kaya *et al.* and Ozudogru *et al.* [71,72]. In the method, the seeds were washed with EtOH (70%) for 5 minutes, H₂O₂ (10%) for 10 minutes, sodium hypochlorite (NaOCl, Domestos®, 20% and 10%) twice for 5 minutes, then rinsed thoroughly with sterile distilled water until detergent residues were removed. The “Gokova” sesame seeds, which became free of contaminants after sterilization, were carried on MS [73] supplemented with 1 mg.l⁻¹ kinetin, 20 g.l⁻¹ sucrose, and 7 g.l⁻¹ agar (pH 5.8) at standard culture conditions [23 ± 2 °C, 16/8 hours light cycle (50 µmol.m⁻².s⁻¹ white cool fluorescent light)] [74]. *In vitro* germinated *S. orientale* cv. “Gökova” micro-shoots were subcultured at 4-week periods and mass propagated to obtain the plant material required for the cell extracts (Figure 7C).



Figure 7. The development of *S. orientale* cv. “Gökova” in the collection garden and *in vitro* nutrient medium (A) The image of the sesame plant growing in the collection garden during the flowering period; (B) The image of the sesame plant growing in the collection garden during the capsule formation period; (C) The image of micro-shoots of *in vitro* grown sesame plant.

4.2. Extraction protocol of *In vitro* Grown Sesame Micro-shoots

The *in vitro* grown micro-shoots of *S. orientale* cv. “Gökova” were left to dry in a fan drying etuv at 35 °C for overnight. Dried plant materials were milled in a grinder with the help of liquid nitrogen. The ground plant was suspended with 99% ethyl alcohol (Merck KGaA, Darmstadt, Germany) as 10 times and subjected to ultrasonic extraction by vortexing. In the extraction process, after each 30-minute cycle, the suspension was precipitated at 4000 rpm for 4 minutes via thermoregulated centrifuge and the supernatant was filtered with the help of filter paper and transferred to the beaker. This process was repeated twice. The obtained extract was collected in an Erlenmeyer flask and a fume hood was used to remove the alcohol from the environment. Thus, crude extract was obtained for use in cell lines. The extract stock solution was prepared with Dimethyl sulfoxide (DMSO) at a concentration of 200 mg.ml⁻¹. Test concentrations to be used in the investigation of *in vitro* cytotoxic effects, wound healing and antiprolative effects on cancer cell lines were prepared by diluting with Dulbecco’s Minimal Essential Medium (DMEM) from this stock [75].

4.3. Cell lines and passage of cell lines

L929 fibroblast (ATCC® CCL-1), A549 lung epithelium (ATCC® CCL-185) and MCF-7 mammary epithelial (ATCC® HTB-22) used as cell lines in the current work were commercially available. The cell lines were amplified in DMEM medium supplemented with 1% antibiotic (penicillin-streptomycin) solution and 10% fetal bovine serum (FBS) at 37 °C in a 5% CO₂ incubator [76].

Each cell line was grown as a monolayer culture in T 25 flasks at 37°C in an oven with 5% CO₂ under 98% humidity, and the flask contained medium was poured when the cells reached approximately 80% density. Cellular debris and serum were removed by washing the surface with sterile D-PBS. In order to separate the monolayer cells from the surface, trypsin EDTA was applied in an amount to cover the cell surface and incubated for about five minutes. The detachment of cells from the surface was followed under an inverted microscope. In order to inhibit the efficacy of trypsin on cell lines with impaired adherence, DMEM containing at least five times the trypsin volume was added. The cells in the flask were pipetted, the cell suspension was taken into a sterile 15 ml falcon and centrifuged at 1200 rpm for 4 minutes. After centrifugal precipitation, the supernatant was removed and the pellet was dissolved in fresh medium (1 ml), inoculated into T 75 flasks and left for incubation [75,76].

4.4. Cytotoxicity Analysis by MTT Method

In vitro cytotoxic effects of *S. orientale* cv. "Gökova" plant extract were determined by 3-(4,5-dimethyl-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) test [77]. The L929 fibroblast cells were used for MTT. The cell lines were grown as monolayer culture on a T 75 flask at 37 °C in an oven with 5% CO₂ under 98% humidity and the medium was removed when the cells reached approximately 80% density. The flask surface was treated with Dulbecco's phosphate-buffered saline (D-PBS) and trypsin was added and incubated for 5 minutes. The cells separated from the surface by the effect of trypsin were suspended with serum-containing DMEM, placed in a sterile 15 ml falcon and centrifuged at 1200 rpm for 4 minutes. After centrifugal precipitation, the supernatant was transferred and the pellet was dissolved in fresh medium (1 ml), and the obtained cell suspension was counted on a thoma slide with Trypan Blue dye. The 3T3 cell suspension was inoculated into 96-well microplates with 200 µl of 1×10^4 cells in each well and incubated for 24 hours at 37 °C, 5% CO₂, and 98% humidity.

After incubation, the culture medium in the plates was emptied and changed with 200 µl of different concentrations of the plant extract in DMEM, and only 200 µl of medium was added to the cell control well. After 24 hours of incubation of the active substance applied plates, the wells were emptied completely and 100 µl of D-PBS was added to each well twice and washed. After washing, 100 µL of fresh medium and 10 µL of MTT were transferred to 1/10 wells and incubated for 3 hours at 37 °C in an oven with 5% CO₂ under 98% humidity.

After this treatment, the wells were emptied and 100 µl of DMSO was added, incubated in a shaker for 25 minutes at room temperature and absorbance was taken at 540 nm. The cell viability in the control well was accepted as 100% and the viability percentage was calculated in the other wells. The inhibitory concentration 50 (IC₅₀, the concentration in which 50% of the cells die) values were calculated statistically in the excel program [77].

The percentage of viable cells was determined by the following formula:

$$\text{Viability (\%)} = [100 \times (\text{Sample}_{\text{abs}}) / (\text{Control}_{\text{abs}})]$$

Sample_{abs}: Absorbance of *S. orientale* cv. "Gökova" applied wells

Control_{abs}: Absorbance of the control well

4.5. *In vitro* Scratch Test

Wound healing activity of *S. orientale* cv. "Gökova" plant extract was determined by *in vitro* scratch test. L929 cells taken from the flask and counted were inoculated as 75×10^4 cells in a 60 mm cell culture dish. A wound was created with a 10 µl micropipette tip on the surface of the cells, which filled nearly 100% of the surface of the cell culture dish in which they were attached for approximately 24-48 hours. While creating the wound, the pipette tip was drawn on the cell culture dish from one end to the other at a constant speed in one go, and the cell lines were cleaned once with D-PBS and the ruptured cells were removed. The cell lines were treated with 2.5 ml of convenient medium [1% antibiotic solution with high glucose ratio and DMEM containing 10% Fetal Bovine Serum (FBS)] containing sub-cytotoxic doses of extract at different concentrations. As the control group, complete medium and solvent with extract solution were prepared at the same concentrations as the sample and transferred to petri dishes. Then, wound line was visualized with phase contrast microscope at 0, 4, 24, and 48 hours, compared with the control group, and wound healing activity was determined [78].

4.6. Determination of the Antiproliferative Effect of Plant Extract in A549 Lung and MCF-7 Mammary Cell Lines by MTT Method

The cells were grown in 1% antibiotic (penicillin-streptomycin) solution with a high glucose ratio and DMEM containing 10% FBS at 37 °C in 5% CO₂. Then, the cell lines were transferred to 96 plates with 1.104 cells in each well and incubated for 24 hours at 37 °C in 5% CO₂. After this step, the mixtures containing fresh medium containing different doses of the active substance were poured

into the wells and incubated again for 24 hours under the same conditions. A row for each concentration was determined on the plates, and the wells in the plates, which were worked with 8 replicates of the same concentration of active substance and 4 repetitions of solvent, were completely emptied after 24 hours of incubation, and 100 µl of D-PBS was added to each well and washed. After washing, 100 µl of fresh medium and 10 µl of MTT were added and incubated for 3 hours at 37 °C in an oven with 5% CO₂ under 98% humidity. After the incubation, the wells were emptied and 100 µl of DMSO was added, incubated in a shaker for 25 minutes at room temperature and absorbance was taken at 540 nm. The cell viability (the formula has been identified in section 4.4.) in the cell control well was accepted as 100%, and % inhibition was calculated according to the viability values in other wells. The inhibitory concentration 50 (IC₅₀, the concentration in which 50% of the cells die) values were calculated statistically in the EXCEL program [79].

$$(\% \text{ inhibition}) = 100 - (\% \text{ viability})$$

4.7. Molecular Analyzes - Determination of Gene Expressions at Transcriptomic Levels

The RNA was extracted from A549 and MCF-7 cell lines using Thermo Scientific™ GeneJET RNA Purification Kit (Cat. No. K0732). The quality and the quantity of the isolated RNAs were determined by spectrophotometer. DNA contamination was eliminated using the Thermo Scientific™ DNase I Solution (1 unit/µl), RNase-free (Cat. No. 89836) Kit. For cDNA synthesis, the total RNAs were reverse transcribed using the OneScript® Plus cDNA Synthesis Kit (Cat. No. G236) and the oligo-dT primers contained in this kit. Amplification of reverse transcribed RNAs was determined by Real-Time PCR using the Ampliqon RealQ Plus 2 × Master Mix Green Kit (Cat. No. A323402) and in the presence of primers for the three genes of interest. The related genes and the sequences of the forward and reverse primers of these genes are given in Table 1. The thermal cycle used in the reaction is 30 seconds of denaturation at 95 °C, followed by 30 seconds of annealing at 55-58 °C and 30 seconds of extension at 72 °C. Real-Time PCR was analyzed by repeating six times. All groups were interpreted by normalizing the expression of beta-actin gene, a housekeeping gene, and using the 2^{-ΔΔCt} (2^{^(-delta delta Ct)}) method. A graph was created by calculating the mean of the obtained values (with standard deviation and standard errors) [80].

The signification of expression levels of the five target genes obtained after qRT-PCR compared to the control group was statistically analyzed by T-Test method. Among the data obtained as a result of the T-Test, those with p ≤ 0.05 were considered statistically significant.

Table 1. Primers and sequences designed for use in Real-Time PCR [81].

Gene Name	Primer Sequens
<i>β-actin</i>	F: 5' TCCTCCTGAGCGCAAGTACTC 3' R: 5' CTGCTTGCTGATCCACATCTG 3'
<i>Cas3</i>	F: 5' GCAGCAAACCTCAGGGAAAC 3' R: 5' TGTCGGCATACTGTTTCAGCA 3'
<i>Cas9</i>	F: 5' GGCTGTCTACGGCACAGATGGA 3' R: 5' CTGGCTCGGGTTACTGCCAG 3'
<i>BCL-XL</i>	F: 5' GCTAGCAGACTTTGGACTAGCCAG 3' R: 5' AGCTCGGTACCACAGGGTCA 3'

5. Conclusions

The current work aimed to investigate the wound healing and anticancer properties of the *in vitro* grown *S. orientale* L. cv. “Gökova” plant extract using L929 fibroblast, A549 lung epithelial, and MCF-7 breast epithelial cell lines. Wounds, especially chronic ones, affect many patients and reduce their quality of life. In this context, it can be said that the plant extract can be effective on wound healing at doses treated with L292 fibroblast cells in our study. On the other hand, in A549 lung epithelial and MCF-7 cell lines treated with the plant extract was to investigate for its anticancer properties and it was also determined that the extract inhibited cell viability at increasing doses. After

animal experiments and clinical applications to be carried out in the future, this plant extract may have the potential to be used in wound healing and/or anticancer drugs. In our study, the expressions of CRISPR-related system 3 (CAS3) endonuclease, CRISPR-related system 9 (CAS9) endonuclease and B-cell lymphoma XL (anti-apoptotic, *BCL-XL*) genes in A549 and MCF-7 cell lines treated with plant extract and cisplatin were also evaluated. The significant increase in these gene expressions indicated that the applied extracts were effective in metabolic processes such as cell growth and division, control of apoptotic pathways and cellular cycle and it can be also said that the applied plant extract has much less toxic compared to cisplatin and it has good anticancer properties. In conclusion, in the light of the data obtained from this study, the *in vitro* grown *S. orientale* L. cv. "Gökova" plant extract can be tested in other cancer cell lines such as colon, liver, cervical, prostate, blood and skin cancer cell lines, in the future. This plant extract also has the potential to make useful contributions to the development of anticancer drugs with animal experiments and clinical applications to be made in the future.

Author Contributions: Conceptualization, E.K., N.S., and A.U.; methodology, E.K., N.S., and A.U.; validation, S.Y., S.G. and I.D.; investigation, S.Y., S.G., and I.D.; data curation, S.Y. and S.G.; writing—original draft preparation, E.K., S.G., and N.S.; writing—review and editing, E.K., N.S., S.Y., S.G., A.U., and I.D.; visualization, S.Y. and S.G.; supervision, E.K., N.S., and A.U.; project administration, E.K., N.S., and A.U.

Funding: This research received no external funding.

Data Availability Statement: The research data supporting this publication are provided within this paper.

Acknowledgments: We would like to thank the employees of Muğla Metropolitan Municipality, Department of Agricultural Services, Muğla Local Seed Center for plant material support.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Anilakumar, K.R.; Pal, A.; Khanum, F.; Bawa, A.S. Nutritional, medicinal and industrial uses of sesame (*Sesamum indicum* L.) seeds - An overview. *Agric. Conspec. Sci.* **2010**, *75*, 159-168. <https://hrcak.srce.hr/66001>
2. Zhang, H.; Miao, H.; Wang, L.; Qu, L.; Liu, H.; Wang, Q.; Yue, M. Genome sequencing of the important oilseed crop *Sesamum indicum* L. *Genome Biol.* **2013**, *14*, 401-410. <https://doi.org/10.1186/gb-2013-14-1-401>
3. Lavaee, F.; Moshaverinia, M.; Malek Hosseini, S.A.; Jamshidzade, A.; Zarei, M.; Jafarian, H.; Haddadi, P.; Badiie, P. Antifungal effect of sesame medicinal herb on *Candida* Species. *Braz. J. Pharm. Sci.* **2019**, *55*, e17479. <https://doi.org/10.1590/s2175-97902019000117479>
4. Sirato-Yasumoto, S.; Katsuta M.; Okuyama Y.; Takahashi, Y.; Ide T. Effect of sesame seeds rich in sesamin and sesamol on fatty acid oxidation in rat liver. *J. Agri. Food Chem.* **2001**, *49*, 2647-2651. <https://doi.org/10.1021/jf001362t>
5. Rokonuzzaman, N.L. Investigation of the analgesic and antioxidant activity from an ethanolic extract of seeds of *Sesamum indicum*. *Pak. J. Biol. Sci.* **2009**, *12*, 595-598. <https://doi.org/10.3923/pjbs.2009.595.598>
6. Smith, D.E.; Salerno, J.W. Selective growth inhibition of a human malignant melanoma cell line by sesame oil *in vitro*. *Prostaglandins Leukot. Essent. Fatty Acids*, **1992**, *46*, 145-150. [https://doi.org/10.1016/0952-3278\(92\)90221-4](https://doi.org/10.1016/0952-3278(92)90221-4)
7. Kamal-Eldin A.; Pettersson, D.; Appelqvist, L.A. Sesamin (a compound from sesame oil) increases tocopherol levels in rats fed ad libitum. *Lipids*, **1995**, *30*, 499-505. <https://doi.org/10.1007/BF02537023>
8. Ogawa, H.; Sasagawa, S.; Murakami, T.; Yoshizumi, H. Sesame lignans modulate cholesterol metabolism in the stroke-prone spontaneously hypertensive rat. *Clin. Exp. Pharmacol. Physiol. Suppl.* **1995**, *1*, 10-12. <https://doi.org/10.1111/j.1440-1681.1995.tb02932.x>
9. Hirata, F.; Fujita, K.; Ishikura, Y.; Hosoda, K.; Ishikawa, T.; Nakamura, H. Hypocholesterolemic effect of sesame lignan in humans. *Atherosclerosis*, **1996**, *122*, 135-136. [https://doi.org/10.1016/0021-9150\(95\)05769-2](https://doi.org/10.1016/0021-9150(95)05769-2)
10. Moazzami, A.A.; Andersson, R.E.; Kamal-Eldin, A. HPLC analysis of sesaminol glucosides in sesame seeds. *J. Agric. Food Chem.* **2006**, *54*, 633-638. <https://doi.org/10.1021/jf051541g>
11. Uzun, B.; Arslan, C.; Furat, S. Variation in fatty acid compositions, oil content and oil yield in germplasm collection of sesame (*Sesamum indicum* L.). *J. Am. Oil. Chem. Soc.* **2008**, *85*, 1135-1142. <https://doi.org/10.1007/s11746-008-1304-0>

12. Williamson, K.S.; Morris, J.B.; Pye, Q.N.; Kamat, C.D.; Hensley, K. A survey of sesamin and composition of tocopherol variability from seeds of eleven diverse sesame (*Sesamum indicum* L.) genotypes using HPLC-PAD-ECD. *Phytochem. Anal.* **2008**, *19*, 311–322. <https://doi.org/10.1002/pca.1050>
13. Pathak, N.; Rai, A.K.; Kumari, R.; Bhat, K.V. Value addition in sesame: A perspective on bioactive components for enhancing utility and profitability. *Pharmacogn. Rev.* **2014**, *8*, 147–155. <https://doi.org/10.4103/0973-7847.134249>
14. Jeng, K.C.G.; Hou, R.C.W. Sesamin and Sesamolin: Nature's Therapeutic Lignans. *Curr. Enzyme Inhib.* **2005**, *1*, 11–20. <https://doi.org/10.2174/1573408052952748>
15. Shimizu, S.; Akimoto, K.; Shinmen, Y.; Kawashima, H.; Sugano, M.; Yamada, H. Sesamin is a potent and specific inhibitor of delta 5 desaturase in polyunsaturated fatty acid biosynthesis. *Lipids* **1991**, *26*, 512–516. <https://doi.org/10.1007/BF02536595>
16. Marchand, P.A.; Zajicek, J.; Lewis, N.G. Oxygen insertion in *Sesamum indicum* furanofuran lignans. Diastereoselective syntheses of enzyme substrate analogues. *Can. J. Chem.* **1997**, *75*, 840–849. <https://doi.org/10.1139/v97-102>
17. Hughes, J. Xenografting: ethical issues. *J. Med. Ethics* **1998**, *24*, 18–24. <https://doi.org/10.1136/jme.24.6.414-a>
18. Lowe, K.C.; Davey, M.R.; Power, J.B. Perfluorochemicals: their applications and benefits to cell culture. *Trends Biotechnol.* **1998**, *16*, 272–277. [https://doi.org/10.1016/S0167-7799\(98\)01205-0](https://doi.org/10.1016/S0167-7799(98)01205-0)
19. Čuperlović-Culf, M.; Barnett, D.A.; Culf, A.S.; Chute, I. Cell culture metabolomics: applications and future directions. *Drug Discov.* **2010**, *15*, 610–621. <https://doi.org/10.1016/j.drudis.2010.06.012>
20. Friedmann, T.; Roblin, R. Gene Therapy for Human Genetic Disease?: Proposals for genetic manipulation in humans raise difficult scientific and ethical problems. *Sci.* **1972**, *175*, 949–955. <https://doi.org/10.1126/science.175.4025.949>
21. Sun, J.; Dai, Z.; Zhao, Y.; Chen, G.Q. *In vitro* effect of oligohydroxyalkanoates on the growth of mouse fibroblast cell line L929. *Biomaterials* **2007**, *28*, 3896–903. <https://doi.org/10.1016/j.biomaterials.2007.05.011>
22. Craciunescu, O.; Moldovan, L.; Moisei, M.; Trif, M. Liposomal formulation of chondroitin sulfate enhances its antioxidant and anti-inflammatory potential in L929 fibroblast cell line. *J. Liposome Res.* **2013**, *23*, 145–53. <https://doi.org/10.3109/08982104.2013.770016>
23. Jeney, F.; Bazsó-Dombi, E.; Oravecz, K.; Szabó, J.; Nagy, I.Z. Cytochemical studies on the fibroblast-preadipocyte relationships in cultured fibroblast cell lines. *Acta Histochem.* **2000**, *102*, 381–389. <https://doi.org/10.1078/0065-1281-00567>
24. Roelofs, B.; Tidball, A.; Lindborg, A.E.; TenHarmsel, A.; Vander Kooy, T.O.; Louters, L.L. Acute activation of glucose uptake by glucose deprivation in L929 fibroblast cells. *Biochimie.* **2006**, *88*, 1941–1946. <https://doi.org/10.1016/j.biochi.2006.08.004>
25. Matysiak, J.; Juszczak, M.; Karpińska, M.M.; Langner, E.; Walczak, K.; Lemieszek, M.K.; Skrzypek, A.; Niewiadomy, A.; Rzeski, W. Synthesis of 2-(2,4-dihydroxyphenyl)thieno-1,3-thiazin-4-ones, their lipophilicity and anticancer activity *in vitro*. *Mol Divers.* **2015**, *19*, 725–736. <https://doi.org/10.1007/s11030-015-9599-x>
26. Kodama, Y.; Baxter, R.C.; Martin, J.L. Insulin-like growth factor-I inhibits cell growth in the a549 non-small lung cancer cell line. *Am. J. Respir. Cell Mol. Biol.* **2002**, *27*, 336–344. <https://doi.org/10.1165/rcmb.2002-0021OC>
27. Comsa, S.; Cimpean, A.M.; Raica, M. The story of MCF-7 breast cancer cell line: 40 years of experience in research. *Anticancer Res.* **2015**, *35*, 3147–3154.
28. Wang, T.T.; Phang, J.M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. *Cancer Res.* **1995**, *55*, 2487–2489.
29. Ramachandran, C.; Fonseca, H.B.; Jhabvala, P.; Escalon, E.A.; Melnick, S.J. Curcumin inhibits telomerase activity through human telomerase reverse transcriptase in MCF-7 breast cancer cell line. *Cancer Lett.* **2002**, *184*, 1–6.
30. Ozols, R.F.; Bundy, B.N.; Greer, B.E.; Fowler, J.M.; Clarke-Pearson, D.; Burger, R.A.; Mannel, R.S.; DeGeest, K.; Hartenbach, E.M.; Baergen, R. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol.* **2003**, *21*, 17, 3194–3200. <https://doi.org/10.1200/JCO.2003.02.153>

31. Kondagunta, G.V.; Bacik, J.; Donadio, A.; Bajorin, D.; Marion, S.; Sheinfeld, J.; Bosl, G.J.; Motzer, R.J. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. *J Clin Oncol.* **2005**, *23*, 6549-6555. <https://doi.org/10.1200/JCO.2005.19.638>
32. Yamamoto, J.; Miyagi, Y.; Kawanishi, K.; Yamada, S.; Miyagi, Y.; Kodama, J.; Yoshinouchi, M.; Kudo, T. Effect of cisplatin on cell death and DNA crosslinking in rat mammary. Adenocarcinoma *in vitro*. *Acta Med Okayama* **1999**, *53*, 201-208. <https://doi.org/10.18926/AMO/31616>
33. Bissett, D.; McLaughlin, K.; Kelland, L.R.; Brown, R. Cisplatin-DNA damage recognition proteins in human tumour extracts. *Br J Cancer.*, **1993**, *67*, 742-748. <https://doi.org/10.1038/bjc.1993.135>
34. Crist, A.M.; Hinkle, K.M.; Wang, X.; Moloney, C.M.; Matchett, B.J.; Labuzan, S.A.; Frankenhauser, I.; Azu, N.O.; Liesinger, A.M.; Lesser, E.R.; Serie, D.J.; Quicksall, Z.S.; Patel, T.A.; Carnwath, T.P.; DeTure, M.; Tang, X.; Petersen, R.C.; Duara, R.; Graff-Radford, N.R.; Allen, M.; Carrasquillo, M.M.; Li, H.; Ross, O.A.; Ertekin-Taner, N.; Dickson, D.W.; Asmann, Y.W.; Carter, R.E.; Murray, M.E. Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer's disease. *Nat. Commun.* **2021**, *12*, 2311. <https://doi.org/10.1038/s41467-021-22399-3>
35. Manechini, J.R.V.; Santos, P.H.D.S.; Romanel, E.; Brito, M.D.S.; Scarpari, M.S.; Jackson, S.; Pinto, L.R.; Vicentini, R. Transcriptomic Analysis of Changes in Gene Expression During Flowering Induction in Sugarcane Under Controlled Photoperiodic Conditions. *Front. Plant Sci.* **2021**, *12*, 635784. <https://doi.org/10.3389/fpls.2021.635784>
36. Uhlen, M.; Karlsson, M.J.; Zhong, W.; Tebani, A.; Pou, C.; Mikes, J.; Lakshmikanth, T.; Forsström, B.; Edfors, F.; Odeberg, J.; Mardinoglu, A.; Zhang, C.; von Feilitzen, K.; Mulder, J.; Sjöstedt, E.; Hober, A.; Oksvold, P.; Zwahlen, M.; Ponten, F.; Lindskog, C.; Sivertsson, Å.; Fagerberg, L.; Brodin, P. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. *Sci.* **2019**, *366*, eaax9198. <https://doi.org/10.1126/science.aax9198>
37. Fagerberg, L.; Hallström, B.M.; Oksvold, P.; Kampf, C.; Djureinovic, D.; Odeberg, J.; Habuka, M.; Tahmasebpour, S.; Danielsson, A.; Edlund, K.; Asplund, A.; Sjöstedt, E.; Lundberg, E.; Szgyarto, C.A.; Skogs, M.; Takanen, J.O.; Berling, H.; Tegel, H.; Mulder, J.; Nilsson, P.; Schwenk, J.M.; Lindskog, C.; Danielsson, F.; Mardinoglu, A.; Sivertsson, A.; von Feilitzen, K.; Forsberg, M.; Zwahlen, M.; Olsson, I.; Navani, S.; Huss, M.; Nielsen, J.; Ponten, F.; Uhlén, M. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol. Cell. Proteomics* **2014**, *13*, 397-406. <https://doi.org/10.1074/mcp.M113.035600>
38. Wolf, J.B. Principles of transcriptome analysis and gene expression quantification: an RNA-seq tutorial. *Mol. Ecol. Resour.* **2013**, *13*, 559-72. <https://doi.org/10.1111/1755-0998.12109>
39. Morozova, O.; Hirst, M.; Marra, M.A. Applications of new sequencing technologies for transcriptome analysis. *Annu. Rev. Genomics Hum. Genet.* **2009**, *10*, 135-51. <https://doi.org/10.1146/annurev-genom-082908-145957>
40. Makarova, K.S.; Wolf, Y.I.; Alkhnbashi, O.S.; Costa, F.; Shah, S.A.; Saunders, S.J.; Barrangou, R.; Brouns, S.J.; Charpentier, E.; Haft, D.H.; Horvath, P.; Moineau, S.; Mojica, F.J.; Terns, R.M.; Terns, M.P.; White, M.F.; Yakunin, A.F.; Garrett, R.A.; van der Oost, J.; Backofen, R.; Koonin, E.V. An updated evolutionary classification of CRISPR-Cas systems. *Nat. Rev. Microbiol.* **2015**, *13*, 722-736. <https://doi.org/10.1038/nrmicro3569>
41. Jinek, M.; Jiang, F.; Taylor, D.W.; Sternberg, S.H.; Kaya, E.; Ma, E.; Anders, C.; Hauer, M.; Zhou, K.; Lin, S.; Kaplan, M.; Iavarone, A.T.; Charpentier, E.; Nogales, E.; Doudna, J.A. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. *Sci.* **2014**, *343*, 1247997. <https://doi.org/10.1126/science.1247997>
42. Loo, L.S.W.; Soetedjo, A.A.P.; Lau, H.H.; Hui Jin Ng, N.; Ghosh, S.; Nguyen, L.; Krishnan, V.G.; Choi, H.; Roca, X.; Hoon, S.; Kee Keong Teo, A. BCL-xL/BCL2L1 is a critical anti-apoptotic protein that promotes the survival of differentiating pancreatic cells from human pluripotent stem cells. *Cell Death Dis.* **2020**, *11*, 378. <https://doi.org/10.1038/s41419-020-2589-7>
43. Farnsworth, N.R.; Soejarto, D.D. Global importance of medicinal plants. *The conservation of medicinal plants* **1991**, *26*, 25-51.
44. Aslam, M.S.; Ahmad, M.S. Worldwide importance of medicinal plants: Current and historical perspectives. *Recent Adv Biol Med.* **2016**, *2*, 909.

45. Kıvrak, Ş.; Göktürk, T.; Kıvrak, İ.; Kaya, E.; Karababa, E. Investigation of Phenolic Profiles and Antioxidant Activities of Some *Salvia* Species Commonly Grown In Southwest Anatolia Using UPLC-ESI-MS/MS. *Food Sci Technol.* **2019**, *2*, 423-431. <https://doi.org/10.1590/fst.32017>
46. Mohammed, A.H. Importance of medicinal plants. *Research in Pharmacy and Health Sciences* **2019**, *5*, 124-125. <https://doi.org/10.32463/rphs.2019.v05i02.01>
47. Kujath, P.; Michelsen, A. Wounds - from physiology to wound dressing. *Dtsch Arztebl Int.* **2008**, *105*, 239-248. <https://doi.org/10.3238/arztebl.2008.0239>
48. Guo, S.; Dipietro, L.A. Factors affecting wound healing. *J Dent Res.* **2010**, *89*, 219-29. <https://doi.org/10.1177/0022034509359125>
49. Wilkinson, H.N.; Hardman, M.J. Wound healing: Cellular mechanisms and pathological outcomes. *Open biology* **2020**, *10*, 200223. <https://doi.org/10.1098/rsob.200223>
50. Bolla, S.R.; Mohammed Al-Subaie, A.; Yousuf Al-Jindan, R.; Papayya Balakrishna, J.; Kanchi Ravi, P.; Veeraraghavan, V.P.; Arumugam Pillai, A.; Gollapalli, S.S.R.; Palpath Joseph, J.; Surapaneni, K.M. *In vitro* wound healing potency of methanolic leaf extract of *Aristolochia saccata* is possibly mediated by its stimulatory effect on collagen-1 expression. *Heliyon* **2019**, *20*, 5, e01648. <https://doi.org/10.1016/j.heliyon.2019.e01648>
51. Alsawalha, M.; Al-Subaie, A.M.; Al-Jindan, R.Y.; Bolla, S.R.; Salahuddin, M.; Veeraraghavan, V.P. Dioscorea villosa Leaf Extract Enhances *in vitro* Wound Healing and Expression of Extra Cellular Matrix Factors Transforming Growth Factor-Beta 1 and Collagen-1 in L929 Cell Lines. *Pharmacogn Mag.* **2019**, *15*, 483-494. https://doi.org/10.4103/pm.pm_81_19
52. Danna, C.; Bazzicalupo, M.; Ingegneri, M.; Smeriglio, A.; Trombetta, D.; Burlando, B.; Cornara, L. Anti-Inflammatory and Wound Healing Properties of Leaf and Rhizome Extracts from the Medicinal Plant *Peucedanum ostruthium* (L.) W. D. J. Koch. *Molecules* **2022**, *27*, 4271. <https://doi.org/10.3390/molecules27134271>
53. Talib, W.H.; Mahasneh, A.M. Antiproliferative Activity of Plant Extracts Used Against Cancer in Traditional Medicine. *Sci Pharm.* **2010**, *78*, 33-46. <https://doi.org/10.3797/scipharm.0912-11>
54. Newman, D.J.; Cragg, G.M.; Snader, K.M. Natural products as sources of new drugs over the period 1981–2002. *J Nat Prod.* **2003**, *66*, 1022–1037. <https://doi.org/10.1021/np030096l>
55. Desai, A.G.; Qazi, G.N.; Ganju, R.K.; El-Tamer, M.; Singh, J.; Saxena, A.K.; Bedi, Y.S.; Taneja, S.C.; Bhat, H.K. Medicinal plants and cancer chemoprevention. *Curr Drug Metab.* **2008**, *9*, 581-591. <https://doi.org/10.2174/138920008785821657>
56. Gutheil, W.G.; Reed, G.; Ray, A.; Anant, S.; Dhar, A. Crocetin: an agent derived from saffron for prevention and therapy for cancer. *Curr Pharm Biotechnol.* **2012**, *13*, 173-179. <https://doi.org/10.2174/138920112798868566>
57. Aggarwal, B.B.; Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. *Biochem Pharmacol.* **2006**, *71*, 1397-421. <https://doi.org/10.1016/j.bcp.2006.02.009>
58. Lee, B.M.; Park, K.K. Beneficial and adverse effects of chemopreventive agents. *Mutat Res.* **2003**, *523*, 265-278. [https://doi.org/10.1016/s0027-5107\(02\)00342-1](https://doi.org/10.1016/s0027-5107(02)00342-1)
59. Nivethitha, R.; Thangavelu, L.; Geetha, R.V.; Anitha, R.; Kumar, R.S.; Raghunandhakumar, S. *In Vitro* Anticancer Effect of *Sesamum Indicum* Extract. *J Complement Med Res.* **2020**, *11*, 99-105.
60. Siao, A.C.; Hou, C.W.; Kao, Y.H.; Jeng, K.C. Effect of sesamin on apoptosis and cell cycle arrest in human breast cancer mcf-7 cells. *Asian Pac J Cancer Prev.* **2015**, *16*, 3779-3783. <https://doi.org/10.7314/apjcp.2015.16.9.3779>
61. Akl, M.R.; Ayoub, N.M.; Abuasal, B.S.; Kaddoumi, A.; Sylvester, P.W. Sesamin synergistically potentiates the anticancer effects of γ -tocotrienol in mammary cancer cell lines. *Fitoterapia.* **2013**, *84*, 347-359. <https://doi.org/10.1016/j.fitote.2012.12.013>
62. Yokota, T.; Matsuzaki, Y.; Koyama, M.; Hitomi, T.; Kawanaka, M.; Enoki-Konishi, M.; Okuyama, Y.; Takayasu, J.; Nishino, H.; Nishikawa, A.; Osawa, T.; Sakai, T. Sesamin, a lignan of sesame, down-regulates cyclin D1 protein expression in human tumor cells. *Cancer Sci.* **2007**, *98*, 1447-1453. <https://doi.org/10.1111/j.1349-7006.2007.00560.x>
63. Watanabe, M.; Iizumi, Y.; Iizuka-Ohashi, M.; Sowa, Y.; Sakai, T. The Pleiotropic Regulation of Cyclin D1 by Newly Identified Sesaminol-Binding Protein ANT2. *Oncogenesis* **2017**, *6*, 1–11. <https://doi.org/10.1038/oncsis.2017.10>

64. Fang, Q.; Zhu, Y.; Wang, Q.; Song, M.; Gao, G.; Zhou, Z. Suppression of Cyclooxygenase-2 Increases Chemosensitivity to Sesamin through the Akt-PI3K Signalling Pathway in Lung Cancer Cells. *Int J Mol Med*. **2019**, 43, 507–516. <https://doi.org/10.3390/molecules24244426>
65. Abdelhamid, G.; El-Kadi, A.O. Buthionine Sulfoximine, an inhibitor of glutathione biosynthesis, induces expression of soluble epoxide hydrolase and markers of cellular hypertrophy in a rat cardiomyoblast cell line: roles of the NF- κ B and MAPK signaling pathways. *Free Radic Bio Med*. **2015**, 82, 1–12.
66. Han, S.S.; Chung, S.T.; Robertson, D.A.; Ranjan, D.; Bondada, S. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. *Clin Immunol*. **1999**, 93, 152–161. <https://doi.org/10.1006/clim.1999.4769>
67. Gabellini, C.; Trisciuoglio, D.; Del Bufalo, D. Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain. *Carcinog*. **2017**, 38, 579–587. <https://doi.org/10.1093/carcin/bgx016>
68. Zhang, H.; Xue, J.; Hessler, P.; Tahir, S.K.; Chen, J.; Jin, S.; Souers, A.J.; Levenson, J.D.; Lam, L.T. Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer. *Mol Cancer* **2015**, 14, 126–135. <https://doi.org/10.1186/s12943-015-0397-y>
69. Mohamadi, N.; Kazemi, S.M.; Mohammadian, M.; Toofani Milani, A.; Moradi, Y.; Yasemi, M.; Ebrahimi far, M.; Mazloumi Tabrizi, M.; Ebrahimi Shahmabadi, H.; Akbarzadeh Khiyavi, A. Toxicity of Cisplatin-Loaded Poly Butyl Cyanoacrylate Nanoparticles in a Brain Cancer Cell Line: Anionic Polymerization Results. *Asian Pac J Cancer Prev*. **2017**, 18, 629–632. <https://doi.org/10.22034/APJCP.2017.18.3.629>
70. Özkan, İ.; Koçak, P.; Yıldırım, M.; Ünsal, N.; Yılmaz, H.; Telci, D.; Şahin, F. Garlic (*Allium sativum*)-derived SEVs inhibit cancer cell proliferation and induce caspase mediated apoptosis. *Sci Rep*. **2021**, 11, 1–11. <https://doi.org/10.1038/s41598-021-93876-4>
71. Ozudogru, E.A.; Kaya, E.; Kirdok, E.; Issever Ozturk, S. *In vitro* propagation from young and mature explants of thyme (*Thymus vulgaris* and *T. longicaulis*) resulting in genetically stable shoots. *In Vitro Cell. Dev. Biol. - Plant* **2011**, 47, 309–320. <https://doi.org/10.1007/s11627-011-9347-6>
72. Kaya, E.; Souza, F.; Yilmaz-Gokdogan, E.; Ceylan, M.; Jenderek, M. Cryopreservation of Citrus Seed via Dehydration Followed by Immersion in Liquid Nitrogen. *Turk. J. Biol.* **2017**, 41, 242–248. <https://doi.org/10.3906/biy-1603-92>
73. Murashige, T.; Skoog, F. A Revised Medium for Rapid Growth and Bio Assays with Tobacco Tissue Cultures. *Plant Physiol.* **1962**, 15, 473–497. <https://doi.org/10.1111/j.1399-3054.1962.tb08052.x>
74. Yeniocak, S.; Kaya, U.; Dal, B.; Şaman, Z.; Galatalı, S.; Kaya, E. Cryopreservation of *Sesamum orientale* L. local cultivar ‘Gökova Sesame’ germplasm. *Trends Cell Biol.* **2022**, 15, 63–68.
75. Abdul Ghafoor, N.; Galatalı, S.; Yeniocak, S.; Kaya, E.; Saraç, N.; Uğur, A. Investigating anticancer potency of *in vitro* propagated endemic *Thymus cilicicus* Boiss. & Bal. extract on human lung, breast, and prostate cancer cell lines. *Biol.* **2022**, 77, 3229–3239. <https://doi.org/10.1007/s11756-022-01168-7>
76. Baygar T. , Saraç N. Antimicrobial activity of clementine peel essential oil with its cytotoxic and *in vitro* wound healing potential on NIH-3T3 fibroblast cells. *Mugla J. Sci. Technol.* **2018**, 4, 143–147. <https://doi.org/10.22531/muglajsci.435610>
77. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **1983**, 65, 55–63. [https://doi.org/10.1016/0022-1759\(83\)90303-4](https://doi.org/10.1016/0022-1759(83)90303-4)
78. Gebäck, T.; Schulz, M.M.; Koumoutsakos, P.; Detmar, M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. *Biotechniques* **2009**, 46, 265–274. <https://doi.org/10.2144/000113083>
79. Van Meerloo, J.; Kaspers, G.J.L.; Cloos, J. Cell sensitivity assays: the MTT assay. In: *Cancer Cell Culture (Methods and Protocols)*, Cree, I., Eds.; Humana Press: New York, 2011; Vol 731. pp. 237–245. https://doi.org/10.1007/978-1-61779-080-5_20
80. Çiçek, S.; Açar, H.; Galatalı, S.; Kaya, E. Transcriptomic Analysis of AREB1 and AREB2 Genes Playing Important Roles in Drought Stress Tolerance in Tomato under *in vitro* Drought Stress. *Environ Anal Ecol Stud.* **2023**, 10, 1203–1209. <https://doi.org/10.31031/EAES.2023.10.000750>
81. Rao, X.; Huang, X.; Zhou, Z.; Lin, X. An improvement of the 2[−]($\Delta\Delta$ CT) method for quantitative real-time polymerase chain reaction data analysis. *Biostat Bioinforma Biomath.* **2013**, 3, 71–85.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.